With liver diseases, HIV/AIDS and cancers as primary therapeutic areas, we develop product pipelines of new anti(retro)viral/anticancer agents based on high throughput screening (HTS) of our molecule library of nucleosides and nucleotides by cell-free enzymatic assays of corresponding nucleotide triphosphates, on technologies of nucleotide prodrugs and on selective targeting viral genomes to cure chronic viral diseases. http://www.apsisglobal.com